Nebula Genomics

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated

Retrieved on: 
torsdag, maj 9, 2024
Project, FDA, Sale, Mayo Clinic, Genomics, Health, Nebula Genomics, Research, Insurance, Collection, Water, Consultant, Genetic testing, Development, Public expenditure, Automation, DNA, SNP, Esophageal cancer, Data, Omicron, Algorithm, Three Months, Patient, CPT, Acquisition, Prophase, Food, Diagnosis, Immunity, Nebula, HRSA, Absorption, COVID-19, Engineering, Medical device

Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.

Key Points: 
  • The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
  • Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
  • Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
  • Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.

Retrieved on: 
torsdag, maj 9, 2024
Project, FDA, Sale, Mayo Clinic, Genomics, Health, Nebula Genomics, Research, Insurance, Collection, Water, Consultant, Genetic testing, Development, Public expenditure, Automation, DNA, SNP, Esophageal cancer, Data, Omicron, Algorithm, Three Months, Patient, CPT, Acquisition, Prophase, Food, Diagnosis, Immunity, Nebula, HRSA, Absorption, COVID-19, Engineering

Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.

Key Points: 
  • The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
  • Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
  • Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
  • Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.

ProPhase Labs Unveils Project ZenQ-AI

Retrieved on: 
tisdag, april 16, 2024
Project, Cancer, Genomics, Whole genome sequencing, Safety, AI, Esophageal cancer, Nebula Genomics, Genetics, Machine learning, WGS, Doctor of Philosophy, DNA, SNP, Therapy, ADC, Marker beacon, Prophase, NVIDIA, Genome, EAC, Database, Diagnosis, CIO, Biomarker, Algorithm, Spacecraft, Medical device

Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (WGS) spanning more than 130 countries, and equivalent to roughly 150 million ancestry SNP-based tests. Whole Genome Sequencing (WGS) offers an exhaustive exploration of an individual’s entire DNA, capturing all three billion base pairs for a complete and detailed genetic blueprint. This comprehensive approach contrasts sharply with SNP tests, which target specific genetic variations at known locations, typically analyzing between 100,000 to 1 million specific points. With WGS providing up to 30,000 times more genetic data than SNP testing, our service delivers unparalleled precision in personalized medicine and genetic research, far beyond the scope of standard SNP testing. Along with the data gathered from the Company’s BE-Smart Test for esophageal adenocarcinoma (EAC), the platform is being utilized to create algorithms that identify possible antibody drug conjugate (ADC) candidates for new cancer therapeutics.

Key Points: 
  • Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI.
  • "The power of Project ZenQ-AI not only stems from cutting-edge AI technology, but also the vast and growing genomic database that we’ve curated and continue to grow," explained Ted Karkus, CEO at ProPhase Labs.
  • To support the computational demands of Project ZenQ-AI, ProPhase Labs is utilizing a dual-approach in technology.
  • ProPhase Labs invites collaboration from across the scientific and medical communities to join in this groundbreaking initiative.

ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives

Retrieved on: 
fredag, mars 15, 2024
Research, WGS, Automation, Genomics, Absorption, Health, Development, Growth, Exercise, Nebula Genomics, COVID-19, Patient, PMI, RNA, Sale, Acquisition, Public expenditure, Food, Engineering, Insurance, Protein, Diagnosis, RNA-Seq, Omicron, Prophase, HRSA, Whole genome sequencing, Marketing, FDA, Genetic counseling, Cryptocurrency

Garden City, NY, March 15, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today reported its financial and operational results for the full-year ended December 31, 2023.

Key Points: 
  • With this significant repositioning completed, Nebula Genomics can now deliver low-cost, high-precision genomic diagnostics across North America and the global market.
  • This agreement presents the possibility for significant expansion of its global footprint and paves the way for prospective future revenue streams.
  • Research and development costs for the year ended December 31, 2023 and 2022 were $1.4 million and $0.7 million, respectively.
  • Diluted earnings per share for the years ended December 31, 2023 and 2022 were $(0.98) and $1.02, respectively.

ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics

Retrieved on: 
tisdag, januari 30, 2024
Prophase, Growth, Whole genome sequencing, Therapy, Karkus, Nebula Genomics, Marketing, Genomics, Acquisition, Health, Nebula, WGS

Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.

Key Points: 
  • Garden City, NY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jason Karkus, one of the driving forces behind ProPhase Diagnostics, becomes President of Nebula Genomics, a wholly-owned subsidiary of ProPhase Labs.
  • This fiscal achievement fueled ProPhase's growth and strategic acquisition of Nebula Genomics.
  • In his new role, Karkus aims to amplify the Nebula Genomics business-to-business operations, as well as its exciting direct-to-consumer Whole Genome Sequencing (WGS) model.
  • As ProPhase focuses on its WGS business lines, Karkus’ leadership, energy and vision are expected to be a driving force.

Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts

Retrieved on: 
tisdag, januari 23, 2024
Name, Esophageal cancer, PMI, Genomics, Nebula Genomics, Therapy, Automation, Engineering, Fine chemical

Garden City, NY, Jan. 23, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today announces significant progress at Pharmaloz Manufacturing, Inc. (PMI), its wholly owned subsidiary.

Key Points: 
  • With the implementation of recent price increases across its entire product line, PMI has transitioned to significant projected 2024 profitability starting with Q1 2024.
  • In addition to the price increases, increased capacity and transition to profitability, PMI has signed deals with two top-tier lozenge brands.
  • One of these brands is also poised to leverage PMI's comprehensive blister packing capabilities, further diversifying its manufacturing portfolio.
  • This production capacity could be further increased, if demand warrants it, with additional staffing to extend the workweek.

ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024

Retrieved on: 
torsdag, januari 4, 2024
Nebula Genomics, CFO, Prophase, Acquisition, Columbia, Genomics, Growth, Acceleration, Therapy, Employment, COVID-19, Property management

Garden City, NY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported that Jed Latkin, a long-time operations and finance expert, has accepted the role as COO of the parent company.

Key Points: 
  • Mr. Latkin, a Columbia MBA, represented the seller in the Company’s acquisition of the BE-SMART Esophageal Cancer Test.
  • Mr. Latkin has been in the finance and management industry since 1996 and has worked with over 15 pharmaceutical companies over the last ten years alone.
  • “We anticipate an acceleration in growth at both Nebula Genomics and Pharmaloz Manufacturing, as well as commercialization of our BE-SMART esophageal cancer test, during 2024.
  • The options have an exercise price of $6.00 per share and will be exercisable for a period of seven years.

ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2023

Retrieved on: 
torsdag, november 9, 2023
Adjustment, TK, FDA, Genetic counseling, Nebula Genomics, Research, Sale, Genomics, Endoscopy, CDX, FDM, Food, Genetic, Heart, Therapy, Hospital Insurance and Diagnostic Services Act, COVID-19 testing, Three Months, History, Public expenditure, Omicron, Diagnosis, EBITDA, Corporation, Absorption, Genetics, Exercise, Prophase, House, Whole genome sequencing, Internet, Health Resources and Services Administration, COVID-19, Medicine, Marketing, Stella, WGS, CPT, Current Procedural Terminology, Patient, Anesthesia, Automation, Antibiotics, Renewable energy, Mobile phone, Clothing, Life insurance, Security (finance), Fine chemical, Birth control, Auction, Broadcasting, Pharmaceutical industry, Cryptocurrency, Bosc

Garden City, NY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three and nine months ended September 30, 2023.

Key Points: 
  • Three Months Ended September 30, 2023 as compared to the Three Months Ended September 30, 2022.
  • Net revenue for the three months ended September 30, 2023 was $8.4 million as compared to $24.2 million for the three months ended September 30, 2022.
  • Diagnostic services costs for the three months ended September 30, 2023 were $0.1 million compared to $2.4 million for the three months ended September 30, 2022.
  • Adjusted EBITDA loss for the three months ended September 30, 2023 was $(2.5) million compared to adjusted EBITDA income of $6.3 million for the three months ended September 30, 2023.

Complete Genomics demonstrates technical and commercial momentum in the sequencing market through new customers, partnerships and collaborations less than one year after launching in the U.S.

Retrieved on: 
tisdag, oktober 31, 2023
Complete Genomics, ASHG, RNA-Seq, Nebula Genomics, Karkus, G400, Whole genome sequencing, IDT, Medical laboratory, Bio-Rad Laboratories, RNA, University of Massachusetts, Face, Professor, Research, SNP, Society, American Society of Human Genetics, Ecosystem, Partnership, WGS, Human genetics, Google AI, Sequoia, Integrated DNA Technologies, Automation, New England Biolabs, Integration, New England, Completeness, Stanford University School of Medicine, Antibiotics, Medical device, Genomics

At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.

Key Points: 
  • At ASHG, Complete Genomics will highlight experts from Stanford Medicine, UMass Chan Medical School and Praxis Genomics to discuss how affordable and accurate genomic sequencing is changing the face of research.
  • See the full description of speakers Complete Genomics is bringing to ASHG at completegenomics.com/ashg-2023-event-page .
  • Based in San Jose, CA, Complete Genomics celebrated its U.S. commercial launch of its DNBSEQ™ sequencing product line one year ago at ASHG 2022.
  • "Our collaboration with Complete Genomics underscores our commitment to providing researchers with advanced solutions for sequencing applications."

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023

Retrieved on: 
torsdag, augusti 10, 2023
Nebula, Mayo Clinic, CPT, Marketing, Internet, George Church, Science, Stella, Nebula Genomics, Patient, Whole genome sequencing, Hospital Insurance and Diagnostic Services Act, Three Months, Automation, HRSA, Heart, Therapy, Diagnosis, Hope, Research, Endoscopy, COVID-19 testing, CLIA, Corporation, Medicine, Genetic, Growth, Prophase, System, CDX, IND, Exercise, DNA, Operation Linebacker, Absorption, History, Genetics, Algorithm, FDM, Omicron, Negotiation, Genomics, Cold, Sale, Public expenditure, Genetic counseling, EBITDA, Food, Renewable energy, Pharmaceutical industry, Retail, Cryptocurrency, Tourism, Fine chemical, Vaccine, Microscope, Q2, COVID-19, Bosc

Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023. The Company announced that despite the slowdown in the Covid-19 testing business, and the significant ramp-up of its multiple growth-oriented subsidiaries, adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million in Q2 and that the Company enjoys robust net working capital of $40.2 million as of June 30, 2023.

Key Points: 
  • Company to hold a conference call Thursday, August 10, 2023, at 11:00 AM ET
    Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023.
  • Revenues grew greater than 100% year-over-year for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022.
  • Three Months Ended June 30, 2023 as compared to the Three Months Ended June 30, 2022.
  • Diagnostic services costs for the three months ended June 30, 2023 were $0.6 million compared to $1.8 million for the three months ended June 30, 2022.